SEARCH

SEARCH BY CITATION

Bibliography

  • 1
    Castell DO & Richter JE. The Esophagus, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 1999: 463–71.
  • 2
    Fennerty MB, Sampliner RE, Garewal HS. Barrett’s oesophagus—cancer risk, biology and therapeutic management. Aliment Pharmacol Ther 1993; 7: 33945.
  • 3
    Ouatu-Lascar R, Fitzgerald RC, Triadofilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 32735.
  • 4
    Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 21208.
  • 5
    Kothari T, Mangla J, Kaira TMS. Barrett’s ulcer and treatment with cimetidine. Arch Int Med 1980; 240: 42578.
  • 6
    Cooper BT & Barbezat GO. Treatment of Barrett’s esophagus with H2 blockers. J Clin Gastroenterol 1987; 9: 2832.
  • 7
    Skinner D, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett’s esophagus: Comparison of benign and malignant cases. Ann Surg 1983; 198: 55466.
  • 8
    Williamson WA, Ellis FH Jr, Gibbs SP, Shuhian DM, Arotz HT. Effect of anti reflux operation on Barrett’s mucosa. Ann Thorac Surg 1990; 49: 53741.
  • 9
    Kuo B & Castell DO. Optimal dosing of omeprazole daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 152731.
  • 10
    Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 13359.
  • 11
    Katz PO, Anderson C, Khoury R, Castell DO. Gastro-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 12314.
  • 12
    Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett’s esophagus. Am J Gastroenterol 1994; 89: 18448.
  • 13
    Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus. Aliment Pharmacol Ther 1998; 12: 8937.DOI: 10.1046/j.1365-2036.1998.00389.x
  • 14
    Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus. Am J Gastroenterol 1997; 92: 5825.
  • 15
    Deviere J, Buset M, Dumocean JM, Richaert F, Cremer M. Regression of Barrett’s epithelium with omeprazole. N Engl J Med 1989; 320: 14978.
  • 16
    Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett’s) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 6238.
  • 17
    Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett’s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 7005.
  • 18
    Katzka DA & Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett’s esophagus. Am J Gastroenterol 1994; 89: 98991.
  • 19
    Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 48994.
  • 20
    Kim SL, Waring JP, Spechler SJ, et al. Diagnostic inconsistencies in Barrett’s esophagus. Gastroenterology 1994; 107: 9459.